Blar i forfatter Det helsevitenskapelige fakultet "Wiseth, Rune"

Viser treff 1-9 av 9

    • Analyses of Increased Mortality in New and Known Diabetes in Patients with Coronary Disease Enrolled in the NORSTENT Randomized Study 

      Mølstad, Per; Nordrehaug, Jan Erik; Steigen, Terje; Wilsgaard, Tom; Wiseth, Rune; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05)
      Background: NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention with drug-eluting stents (DES) or bare-metal stents (BMS) with a 5-year follow-up. Among the patients, 5,512 had measured either fasting glucose level or percent glycated hemoglobin (HbA1c) at the index procedure. That cohort constitutes the present study population analyzing mortality and evaluating treatment ...

    • Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Study 

      Mølstad, Per; Nordrehaug, Jan Erik; Steigen, Terje; Wilsgaard, Tom; Wiseth, Rune; Rotevatn, Svein; Mannsverk, Jan Torbjørn; Larsen, Tommy; Larsby, Kristina; Skarstad, Sigrun; Fosse, Eivind Øygard; Dahl-Eriksen, Øystein; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-01)
      Background: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary ...

    • The effect of drug-eluting stents on target lesion revascularization in native coronary arteries: Results from the NORSTENT randomized study 

      Mølstad, Per; Nordrehaug, Jan Erik; Steigen, Terje; Melvær, Giil Lasse; Wilsgaard, Tom; Wiseth, Rune; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-06)
      <i>Background</i>: The NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) or bare-metal stent (BMS) with 5-year follow-up. No difference was found in the composite primary outcome of death from any cause and nonfatal spontaneous myocardial infarction after a median of 5 years of follow-up. Secondary outcomes included repeat ...

    • IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction 

      Orrem, Hilde Lang; Nilsson, Per; Pischke, Søren Erik; Kleveland, Ola; Yndestad, Arne; Ekholt, Karin; Damås, Jan Kristian; Espevik, Terje; Bendz, Bjørn; Halvorsen, Bente; Gregersen, Ida; Wiseth, Rune; Andersen, Geir Øystein; Ueland, Thor; Gullestad, Lars; Aukrust, Pål; Barratt-Due, Andreas; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-12)
      <p><i>Background</i>: Elevated interleukin-6 (IL-6) and complement activation are associated with detrimental effects of inflammation in coronary artery disease (CAD). The complement anaphylatoxins C5a and C3a interact with their receptors; the highly inflammatory C5aR1, and the C5aR2 and C3aR. We evaluated the effect of the IL-6 receptor (IL-6R)-antagonist tocilizumab on the expression of the ...

    • Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction 

      Kleveland, Ola; Ueland, Thor; Kunszt, Gabor; Bratlie, Marte; Yndestad, Arne; Broch, Kaspar; Holte, Espen; Ryan, Liv; Amundsen, Brage H.; Bendz, Bjørn; Aakhus, Svend; Espevik, Terje; Halvorsen, Bente; Mollnes, Tom Eirik; Wiseth, Rune; Gullestad, Lars; Aukrust, Pål; Damås, Jan Kristian (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-06-29)
      <p><i>Aim</i>: To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network in patients with acute non-ST-elevation myocardial infarction (NSTEMI).</p> <p><i>Methods</i>: 117 patients with acute NSTEMI were randomised to an intravenous infusion of 280 mg tocilizumab or placebo prior to coronary angiography. Blood samples were obtained at baseline, at 6 consecutive ...

    • Pasientvolum og behandlingskvalitet ved hjerte- og karsykdommer 

      Norderhaug, Inger Natvig; Ingebrigsten, Tor; Krogstad, Unni; Søreide, Odd; Myhre, Hans Olav; Wiseth, Rune (Research report; Forskningsrapport, 2007)
      Kunnskapssenteret har gjennomgått og sammenstilt forskningen om pasientvolum og behandlingskvalitet med grunnlag i litteratur for perioden 2001–2006. Denne delrapporten tar for seg behandling av hjerte- og karsykdommer.The influence of hospital or physician volume on qality of health care

    • Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction 

      Broch, Kaspar; Anstensrud, Anne Kristine; Woxholt, Sindre; Sharma, Kapil Kishore; Tøllefsen, Ingvild Maria; Bendz, Bjørn; Aakhus, Svend; Ueland, Thor; Amundsen, Brage H.; Damås, Jan Kristian; Berg, Erlend; Bjørkelund, Elisabeth; Bendz, Christina; Hopp, Einar; Kleveland, Ola; Stensæth, Knut Haakon; Opdahl, Anders; Kløw, Nils-Einar; Seljeflot, Ingebjørg; Andersen, Geir Øystein; Wiseth, Rune; Aukrust, Pål; Gullestad, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-04-12)
      <p><i>Background - </i>Prompt myocardial revascularization with percutaneous coronary intervention (PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI). However, as much as 50% of the loss of viable myocardium may be attributed to the reperfusion injury and the associated inflammatory response. <p><i>Objectives - </i>This study sought ...

    • Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction 

      Ueland, Thor; Kleveland, Ola; Michelsen, Annika; Wiseth, Rune; Damås, Jan Kristian; Aukrust, Pål; Gullestad, Lars; Halvorsen, Bente; Yndestad, Arne (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-18)
      <p><i>Objective</i>: It is unclear if activation of inflammatory pathways regulates proprotein convertase subtilisin-kexin type 9 (PCSK9) levels.</p> <p><i>Approach</i>: We evaluated (1) the temporal course of serum PCSK9 during hospitalisation following acute coronary syndrome and associations with markers of inflammation (leucocyte counts, interleukin (IL)-6, C-reactive protein) and lipid levels ...

    • Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction 

      Helseth, Ragnhild; Kleveland, Ola; Ueland, Thor; Wiseth, Rune; Damås, Jan Kristian; Broch, Kaspar; Michelsen, Annika Elisabet; Bendz, Bjørn; Gullestad, Lars; Aukrust, Pål; Seljeflot, Ingebjørg (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05-10)
      Objective: Beyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to formation of neutrophil extracellular traps (NETs), carrying inflammatory and thrombotic properties.<p> <p>Methods - In a placebo-controlled ...